Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
Mario Sznol
Consultant or Advisory Role - Bristol-Myers Squibb
Harriet M. Kluger
No relevant relationships to disclose
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U)
David F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb
Richard D. Carvajal
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Donald P. Lawrence
No relevant relationships to disclose
Suzanne Louise Topalian
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Other Remuneration - Amplimmune (I); Bristol-Myers Squibb (I)
Michael B. Atkins
Consultant or Advisory Role - Bristol-Myers Squibb
John D. Powderly
Employment or Leadership Position - BioCytics
Consultant or Advisory Role - Amplimmune; Bristol-Myers Squibb; Roche/Genentech
Stock Ownership - BioCytics
Honoraria - Bristol-Myers Squibb; Dendreon; Genentech
Research Funding - Amgen; Amplimmune; Bristol-Myers Squibb; Celldex; Genentech; ImClone Systems; Lilly; Millennium; Progenics; Regeneron
William Howard Sharfman
Consultant or Advisory Role - Merck
Igor Puzanov
No relevant relationships to disclose
David C. Smith
Research Funding - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Georgia Kollia
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jeffrey Alan Sosman
Consultant or Advisory Role - Genentech
Research Funding - Bristol-Myers Squibb